Picture loading failed.

Anti-CTLA4;PDCD1 therapeutic antibody (Pre-made Vudalimab biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Vudalimab (formerly XmAb 20717 or XmAb 717) is a bispecific antibody being developed by Xencor, for the treatment of solid tumours. Xencor is using its Xtend Fc domain technology (a part of Xencor's proprietary XmAb? technology) that increases binding affinity to the receptor FcRn.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-631-1mg 1mg 3090
GMP-Bios-ab-631-10mg 10mg 21890
GMP-Bios-ab-631-100mg 100mg 148000
GMP-Bios-ab-631-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CTLA4;PDCD1 therapeutic antibody (Pre-made Vudalimab biosimilar,Bispecific Mixed mAb and scFv)
INN Name Vudalimab
FormatBispecific Mixed mAb and scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI Structure5tru:HL/5xj3:DE/6jc2:HL/6rp8:hl;None
Year Proposed2020
Year Recommended2021
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Development Techna